OPPORTUNITY TO MEET THE NEEDS OF CANCER PATIENTS WITH LIMITED TREATMENT CHOICES

Every year, more than a million and a half people are diagnosed with cancer in the US, and almost 1,700 people die from this disease per day. Though the survival rate as a whole has increased over the last decades, progress in therapeutic approaches has been incredibly variable, and for certain types of cancers (lung, colorectal, pancreatic), advances have been incrementally modest and unsatisfactory. Bantam is committed to developing therapeutics that address unmet needs of cancer patients.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

National Cancer Institute estimates 72,240 new cases of non-Hodgkin Lymphoma (NHL) in 2017.
DLBCL is an aggressive sub-type of NHL

BANTAM & DLBCL

Bantam’s lead compounds induce prolonged tumor regression and apoptosis in different DLBCLs. The compounds may represent new therapeutics for relapsed and/or refractory DLBCL.

KRAS MUTANT CANCERS

The American Cancer Society estimates that 411,000 people will be diagnosed with some form of KRAS mutated cancer (colorectal, lung or pancreatic) in 2017.

BANTAM & KRAS

Pre-clinical in vitro & in vivo data indicate that cancers with a KRAS mutation are responsive to Bantam’s compounds.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Diffuse Large B-Cell Lymphoma is a common form of non-Hodgkin’s lymphoma and the current standard of care, chemo-immunotherapy (R-CHOP),  provides remission and survival for 50% of patients. Bantam’s lead candidates induce apoptosis in a wide array of DLBCL cell lines including ABC and GCB subtypes and those characterized by Myc and Bcl-2 genomic alterations (“double-hit” lymphomas). Our compounds induce rapid and sustained tumor regression in in vivo xenograft models of B-Cell Lymphoma. The compounds represent a new potential therapeutic approach that will expand the treatment options available for relapsed and refractory DLBCL; a market opportunity that exceeds $1 billion annually.

KRAS MUTATED SOLID TUMORS

Based on pre-clinical in vitro and in vivo data, cancers with a KRAS mutation are more likely to respond to Bantam’s compounds than cancers without the mutation. KRAS is a frequent “driver” mutation of three of the four most lethal cancers: colorectal, lung adenocarcinoma, and pancreatic adenocarcinoma. The KRAS oncology market represents a substantial unmet need for cancer patients and collectively encompasses greater than a $9 billion annual market potential.